drugset / Trial / NCT05182034
Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K\&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee - i.e., the more severely affected knee), and enroll in this study.
Timeline
- Start
- 2022-02-24
- Primary completion
- 2023-10-17
- Completion
- 2023-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SMUP-IA-01 | Cell therapy | 2 ml | Other |
| Subject | SMUP-IA-01 | Cell therapy | 4e+06 cells | Other |
| Subject | SMUP-IA-01 | Cell therapy | 1e+07 cells | Other |